A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158

Last updated date
Study Location
Clinical Research Atlanta
Stockbridge, Georgia, 30281, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-49 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy women ≥18 and ≤49 years of age who are of childbearing potential or not of childbearing potential. (Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.)

- Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures.

- Expected to be available for the duration of the study and can be contacted by telephone during study participation.

- Body mass index (BMI) of <40 kg/m2 at the time of the consent.

- Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed within.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the participant inappropriate for entry into
this study.


- Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
hepatitis B virus (HBV).


- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the vaccines being administered in the
study.


- History of latex allergy.


- Immunocompromised participants with known or suspected immunodeficiency, as determined
by history, laboratory tests, and/or physical examination.


- Any contraindication to Tdap (including encephalopathies).


- History of autoimmune disease or an active autoimmune disease requiring therapeutic
intervention, including but not limited to systemic or cutaneous lupus erythematosus,
autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple
sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura,
glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis),
psoriasis, and insulin dependent diabetes mellitus (type 1).


- Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.


- Women who are pregnant or breastfeeding.


- Previous vaccination with any licensed or investigational RSV vaccine, or planned
receipt of nonstudy RSV vaccine throughout the study.


- Treatment with immunosuppressive therapy, including cytotoxic agents or systemic
corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt
throughout the study. If systemic corticosteroids have been administered short term
(<14 days) for treatment of an acute illness, participants should not be enrolled into
the study until corticosteroid therapy has been discontinued for at least 28 days
before investigational product administration. Inhaled/nebulized, intra-articular,
intrabursal, or topical (skin or eyes) corticosteroids are permitted.


- Receipt of blood/plasma products or immunoglobulin within 60 days before
investigational product administration or planned receipt throughout the study.


- Current alcohol abuse, marijuana abuse, or illicit drug use.


- Vaccination within 5 years with DTaP or tetanus and diphtheria toxoids adsorbed (Td)
vaccine before investigational product administration.


- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Pfizer employees, including their family members, directly involved in the conduct of
the study.


- Current febrile illness (oral temperature ≥38.0C [≥100.4F]) or other acute illness
within 48 hours before investigational product administration.


- Receipt of any inactivated vaccine within 14 days and any live vaccine within 28 days
before or anticipated receipt of any vaccine within the 14 days after investigational
product administration.


- Receipt of short-term (<14 days) systemic corticosteroids. Investigational product
administration should be delayed until systemic corticosteroid use has been
discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or
topical (skin or eyes) corticosteroids do not require temporary delay of
investigational product administration.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Phoenix, Arizona
  2. Tucson, Arizona
  3. Tucson, Arizona
  4. Chowchilla, California
  5. Huntington Park, California
  6. Huntington Park, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Madera, California
  10. Madera, California
  11. Madera, California
  12. Madera, California
  13. Loxahatchee Groves, Florida
  14. North Miami Beach, Florida
  15. North Miami Beach, Florida
  16. Columbus, Georgia
  17. Columbus, Georgia
  18. Blackfoot, Idaho
  19. Blackfoot, Idaho
  20. Blackfoot, Idaho
  21. Nampa, Idaho
  22. Nampa, Idaho
  23. Nampa, Idaho
  24. Pocatello, Idaho
  25. Pocatello, Idaho
  26. El Dorado, Kansas
  27. Newton, Kansas
  28. Wichita, Kansas
  29. Wichita, Kansas
  30. Alexandria, Louisiana
  31. Alexandria, Louisiana
  32. Metairie, Louisiana
  33. Blaine, Minnesota
  34. Coon Rapids, Minnesota
  35. Coon Rapids, Minnesota
  36. Coon Rapids, Minnesota
  37. Coon Rapids, Minnesota
  38. Maple Grove, Minnesota
  39. Minneapolis, Minnesota
  40. Minneapolis, Minnesota
  41. Minneapolis, Minnesota
  42. Saint Louis, Missouri
  43. Butte, Montana
  44. Great Falls, Montana
  45. Helena, Montana
  46. Kalispell, Montana
  47. Missoula, Montana
  48. Lincoln, Nebraska
  49. Lincoln, Nebraska
  50. Lincoln, Nebraska
  51. Norfolk, Nebraska
  52. Dayton, Ohio
  53. Englewood, Ohio
  54. Yukon, Oklahoma
  55. Summerville, South Carolina
  56. Summerville, South Carolina
  57. Austin, Texas
  58. Beaumont, Texas
  59. Beaumont, Texas
  60. Beaumont, Texas
  61. Beaumont, Texas
  62. Burleson, Texas
  63. Fort Worth, Texas
  64. Fort Worth, Texas
  65. Galveston, Texas
  66. Georgetown, Texas
  67. Georgetown, Texas
  68. Georgetown, Texas
  69. Georgetown, Texas
  70. Grapevine, Texas
  71. Houston, Texas
  72. Houston, Texas
  73. Houston, Texas
  74. Houston, Texas
  75. Houston, Texas
  76. Lampasas, Texas
  77. Lampasas, Texas
  78. Longview, Texas
  79. Longview, Texas
  80. Longview, Texas
  81. Longview, Texas
  82. McAllen, Texas
  83. Plano, Texas
  84. San Antonio, Texas
  85. Tomball, Texas
  86. Murray, Utah
  87. Salt Lake City, Utah
  88. Salt Lake City, Utah
  89. Salt Lake City, Utah
  90. Norfolk, Virginia
  91. Norfolk, Virginia
  92. Richmond, Virginia
  93. Richmond, Virginia
  94. Richmond, Virginia
  95. Richmond, Virginia
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Beaumont, Texas
  2. Fort Worth, Texas
  3. San Miguel de Tucuman, Tucuman
  4. San Miguel de Tucuman, Tucuman
  5. Salta,
  6. Clayton, Victoria
  7. Mount Lawley, Western Australia
  8. Murdoch, Western Australia
  9. Nedlands, Western Australia
  10. Subiaco, Western Australia
  11. Subiaco, Western Australia
  12. Santiago, Region Metropolitana
  13. Santiago, Región Metropolitana
  14. Santiago, Región Metropolitana
  15. Christchurch,
  16. Christchurch,
  17. Christchurch,
  18. Christchurch,
  19. Lincoln,
  20. Rangiora,
  21. Birmingham, Alabama
  22. Birmingham, Alabama
  23. Birmingham, Alabama
  24. Cullman, Alabama
  25. Cullman, Alabama
  26. Cullman, Alabama
  27. Phoenix, Arizona
  28. Tucson, Arizona
  29. Tucson, Arizona
  30. Tucson, Arizona
  31. Chowchilla, California
  32. Huntington Park, California
  33. Huntington Park, California
  34. Los Angeles, California
  35. Madera, California
  36. Madera, California
  37. Madera, California
  38. Madera, California
  39. Aurora, Colorado
  40. Aurora, Colorado
  41. Aurora, Colorado
  42. Aurora, Colorado
  43. Aurora, Colorado
  44. Aurora, Colorado
  45. Aurora, Colorado
  46. Atlanta, Georgia
  47. Blackfoot, Idaho
  48. Blackfoot, Idaho
  49. Blackfoot, Idaho
  50. Idaho Falls, Idaho
  51. Idaho Falls, Idaho
  52. Idaho Falls, Idaho
  53. Idaho Falls, Idaho
  54. Idaho Falls, Idaho
  55. Idaho Falls, Idaho
  56. Nampa, Idaho
  57. Nampa, Idaho
  58. Nampa, Idaho
  59. Pocatello, Idaho
  60. Pocatello, Idaho
  61. Ankeny, Iowa
  62. West Des Moines, Iowa
  63. West Des Moines, Iowa
  64. El Dorado, Kansas
  65. Hutchinson, Kansas
  66. Alexandria, Louisiana
  67. Metairie, Louisiana
  68. Blaine, Minnesota
  69. Coon Rapids, Minnesota
  70. Coon Rapids, Minnesota
  71. Coon Rapids, Minnesota
  72. Coon Rapids, Minnesota
  73. Minneapolis, Minnesota
  74. Biloxi, Mississippi
  75. Gulfport, Mississippi
  76. Gulfport, Mississippi
  77. Gulfport, Mississippi
  78. Saint Louis, Missouri
  79. Saint Louis, Missouri
  80. Saint Louis, Missouri
  81. Missoula, Montana
  82. Missoula, Montana
  83. Lincoln, Nebraska
  84. Lincoln, Nebraska
  85. Lincoln, Nebraska
  86. Norfolk, Nebraska
  87. Albuquerque, New Mexico
  88. Binghamton, New York
  89. Endwell, New York
  90. Hempstead, New York
  91. Johnson City, New York
  92. Johnson City, New York
  93. Mineola, New York
  94. Mineola, New York
  95. Mineola, New York
  96. Mineola, New York
  97. Rochester, New York
  98. Rochester, New York
  99. Durham, North Carolina
  100. Durham, North Carolina
  101. Durham, North Carolina
  102. Durham, North Carolina
  103. Dayton, Ohio
  104. Dayton, Ohio
  105. Englewood, Ohio
  106. Kettering, Ohio
  107. Summerville, South Carolina
  108. Summerville, South Carolina
  109. Summerville, South Carolina
  110. Beaumont, Texas
  111. Beaumont, Texas
  112. Beaumont, Texas
  113. Fort Worth, Texas
  114. Galveston, Texas
  115. Georgetown, Texas
  116. Georgetown, Texas
  117. Georgetown, Texas
  118. Georgetown, Texas
  119. Houston, Texas
  120. Houston, Texas
  121. Houston, Texas
  122. Houston, Texas
  123. Lampasas, Texas
  124. Lampasas, Texas
  125. Longview, Texas
  126. Longview, Texas
  127. McAllen, Texas
  128. Pharr, Texas
  129. Plano, Texas
  130. Plano, Texas
  131. Tomball, Texas
  132. Murray, Utah
  133. Salt Lake City, Utah
  134. Salt Lake City, Utah
  135. Salt Lake City, Utah
  136. Richmond, Virginia
  137. Richmond, Virginia
  138. Huntington, West Virginia
  139. Huntington, West Virginia
  140. Huntington, West Virginia
  141. Huntington, West Virginia
  142. Osorno, Región DE LOS Lagos
  143. Santiago, Región Metropolitana
  144. Santiago, Región Metropolitana
  145. Wellington,
  146. Soweto, Gauteng
  147. Soweto,
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
Official Title  ICMJE A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Brief Summary This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age. This study will evaluate non-inferiority of RSV vaccine when given with Tdap and vice-versa.
Detailed Description

This Phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age.

The participants will be equally split into 5 treatment groups: One of a possible two dose levels of RSV vaccine (the higher dose level will be formulated with an aluminum hydroxide adjuvant) with either the Tdap or Placebo, or a Tdap and placebo combination.

This study will evaluate non-inferiority of the Tdap when co-administered with RSV vaccine candidate and vice-versa by measuring participants' immune response through appropriate antibody and component levels 1 month after vaccination.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: RSV Vaccine
    RSV vaccine
  • Biological: Tdap
    Tetanus, Diphtheria, and Acellular Pertussis Vaccine
  • Biological: Placebo
    Normal saline solution for injection (0.9% sodium chloride injection)
Study Arms  ICMJE
  • Experimental: Lower RSV vaccine dose and Tdap
    Lower RSV vaccine dose and Tdap
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Tdap
  • Experimental: Lower RSV vaccine dose and Placebo
    Lower RSV vaccine dose and Placebo
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Placebo
  • Experimental: Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
    Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Tdap
  • Experimental: Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
    Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Placebo
  • Placebo Comparator: Placebo and Tdap
    Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
    Interventions:
    • Biological: Tdap
    • Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 20, 2020)
712
Original Estimated Enrollment  ICMJE
 (submitted: August 26, 2019)
680
Actual Study Completion Date  ICMJE December 11, 2019
Actual Primary Completion Date December 11, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy women ?18 and ?49 years of age who are of childbearing potential or not of childbearing potential. (Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.)
  • Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures.
  • Expected to be available for the duration of the study and can be contacted by telephone during study participation.
  • Body mass index (BMI) of <40 kg/m2 at the time of the consent.
  • Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed within.

Exclusion Criteria:

  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the vaccines being administered in the study.
  • History of latex allergy.
  • Immunocompromised participants with known or suspected immunodeficiency, as determined by history, laboratory tests, and/or physical examination.
  • Any contraindication to Tdap (including encephalopathies).
  • History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin dependent diabetes mellitus (type 1).
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any licensed or investigational RSV vaccine, or planned receipt of nonstudy RSV vaccine throughout the study.
  • Treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Receipt of blood/plasma products or immunoglobulin within 60 days before investigational product administration or planned receipt throughout the study.
  • Current alcohol abuse, marijuana abuse, or illicit drug use.
  • Vaccination within 5 years with DTaP or tetanus and diphtheria toxoids adsorbed (Td) vaccine before investigational product administration.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Current febrile illness (oral temperature ?38.0C [?100.4F]) or other acute illness within 48 hours before investigational product administration.
  • Receipt of any inactivated vaccine within 14 days and any live vaccine within 28 days before or anticipated receipt of any vaccine within the 14 days after investigational product administration.
  • Receipt of short-term (<14 days) systemic corticosteroids. Investigational product administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids do not require temporary delay of investigational product administration.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:Healthy, non-pregnant women 18 to 49 years of age, who are of childbearing potential or not of childbearing potential.
Ages  ICMJE 18 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04071158
Other Study ID Numbers  ICMJE C3671004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP